Clal Insurance’s UroGen Pharma URGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-222,159
| Closed | -$3.11M | – | 133 |
|
|
2023
Q3 | $3.11M | Sell |
222,159
-307,229
| -58% | -$4.3M | 0.04% | 84 |
|
|
2023
Q2 | $5.48M | Hold |
529,388
| – | – | 0.07% | 91 |
|
|
2023
Q1 | $4.89M | Hold |
529,388
| – | – | 0.07% | 91 |
|
|
2022
Q4 | $4.7M | Hold |
529,388
| – | – | 0.07% | 104 |
|
|
2022
Q3 | $4.41M | Hold |
529,388
| – | – | 0.06% | 112 |
|
|
2022
Q2 | $4.34M | Hold |
529,388
| – | – | 0.06% | 112 |
|
|
2022
Q1 | $4.61M | Hold |
529,388
| – | – | 0.05% | 114 |
|
|
2021
Q4 | $5.03M | Hold |
529,388
| – | – | 0.05% | 120 |
|
|
2021
Q3 | $8.9M | Hold |
529,388
| – | – | 0.1% | 115 |
|
|
2021
Q2 | $8.08M | Hold |
529,388
| – | – | 0.09% | 114 |
|
|
2021
Q1 | $10.3M | Hold |
529,388
| – | – | 0.12% | 112 |
|
|
2020
Q4 | $8.91M | Hold |
529,388
| – | – | 0.12% | 94 |
|
|
2020
Q3 | $10.2M | Hold |
529,388
| – | – | 0.17% | 88 |
|
|
2020
Q2 | $13.8M | Hold |
529,388
| – | – | 0.27% | 78 |
|
|
2020
Q1 | $9.44M | Buy |
529,388
+511,722
| +2,897% | +$9.13M | 0.24% | 76 |
|
|
2019
Q4 | $529K | Sell |
17,666
-511,722
| -97% | -$15.3M | 0.57% | 46 |
|
|
2019
Q3 | $12.6M | Sell |
529,388
-24,390
| -4% | -$581K | 0.31% | 66 |
|
|
2019
Q2 | $19.9M | Sell |
553,778
-1,196
| -0.2% | -$43K | 0.46% | 52 |
|
|
2019
Q1 | $20.5M | Buy |
554,974
+155,712
| +39% | +$5.75M | 0.5% | 47 |
|
|
2018
Q4 | $17.2M | Buy |
399,262
+89,262
| +29% | +$3.84M | 0.45% | 45 |
|
|
2018
Q3 | $14.6M | Hold |
310,000
| – | – | 0.39% | 38 |
|
|
2018
Q2 | $15.4M | Buy |
310,000
+26,500
| +9% | +$1.32M | 0.4% | 34 |
|
|
2018
Q1 | $14.1M | Buy |
283,500
+279,039
| +6,255% | +$13.9M | 0.37% | 31 |
|
|
2017
Q4 | $166K | Buy |
+4,461
| New | +$166K | ﹤0.01% | 61 |
|